ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
5 hedge funds and large institutions have $596K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
27% more capital invested
Capital invested by funds: $468K → $596K (+$128K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$36.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$29.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$57.1K |
| 2 |
Morgan Stanley
New York
|
-$13.9K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $294K | -$57.1K | -3,834 | -18% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $211K | +$36.5K | +2,449 | +24% |
|
|
3
UBS Group
Zurich,
Switzerland
| $57K | +$19.2K | +1,287 | +61% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $33K | +$29.5K | +1,984 | New |
|
|
5
Morgan Stanley
New York
| $1K | -$13.9K | -931 | -94% |
|
|
CG
6
Cutler Group
San Francisco,
California
| – | -$5K | -399 | Closed |
|
ZBIO Hedge Fund Activity: Q3 2019 in Review
5 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q3 2019, worth a combined $596K — up 27% from $468K a quarter earlier.
Fund positioning in ZBIO was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $36.5K. The largest seller was Citadel Advisors, cutting an estimated $57.1K.
- 5 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $596K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q3 2019, up 27% quarter-over-quarter.
- 1 fund opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q3 2019 and 1 closed out, a net change of 0 holders.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q3 2019 was Susquehanna International Group, an estimated $36.5K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q3 2019 was Citadel Advisors, an estimated $57.1K sold.
Based on aggregated 13F filings for Q3 2019.